The crying that the game is rigged is a wasted exercise. Most executives who have been in a small Pharma company with no drugs approved know it’s an uphill battle and deal with it . It’s challenging when you have no money to lobby and build relationships with the federal powers that be . That’s why many of these little companies partner early on with large pharmas so they show up on the radar of the bureaucracy in place. We decided not to do that and go it alone or we didn’t get any takers early on . We will never know what the story is on that. But we know the management team and the Board wants a partner now and I believe there is a lot of work going on to get one. I think one issue may be holding things up is the drug safety complaint the fda had so we need to ensure that roadblock is addressed as a high priority. But I believe if the top line data that was promised 5 months ago shows a clear value for some/ many NASH patients , along with a go from the fda on its safety, we will sign a large partner to pay for the phase 3 trial . They will also get the licensing rights to the drug while Cytodyn gets a very large sum of of cash for those rights along with a cut of the profits. Just my opinion